Literature DB >> 17085766

Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth.

Mary C Long1, Paula W Allan, Mei-Zhen Luo, Mao-Chin Liu, Alan C Sartorelli, William B Parker.   

Abstract

OBJECTIVES: Analyse a series of halogenated 3-deaza-adenosine analogues for efficacy against Mycobacterium tuberculosis H37Ra and determine if adenosine (Ado) kinase plays a role in the mechanism of action of these compounds.
METHODS: The MIC as determined by microdilution broth assay provided a measure of antitubercular efficacy. MIC values were measured in M. tuberculosis strains H37Ra, SRICK1 (an Ado kinase-deficient strain of M. tuberculosis derived from H37Ra) and SRICK1 complemented with adoK, the gene which codes for Ado kinase in M. tuberculosis, in order to determine if Ado kinase played a role in the mechanism of action of these compounds. Furthermore, each compound was analysed as both a substrate and inhibitor for purified Ado kinases from M. tuberculosis and human sources.
RESULTS: 2-Fluoro-3-deaza-adenosine, 3-fluoro-3-deaza-adenosine and 2,3-difluoro-3-deaza-adenosine exhibited antitubercular activity that was Ado kinase-dependent. Furthermore, these compounds were at least 10-fold better substrates for M. tuberculosis Ado kinase than the human homologue.
CONCLUSIONS: The Ado kinase-dependent antitubercular activity exhibited by several of the halogenated 3-deaza-adenosine analogues investigated in this study warrants further investigation of these compounds as antitubercular agents. Furthermore, substrate and inhibition studies provided insight into the Ado-binding domain of Ado kinase, indicating that steric hindrance may limit the size of exocyclic modifications at the 3-position of Ado.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085766     DOI: 10.1093/jac/dkl448

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

2.  Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety.

Authors:  Mary C Long; Sue C Shaddix; Omar Moukha-Chafiq; Joseph A Maddry; Lisa Nagy; William B Parker
Journal:  Biochem Pharmacol       Date:  2008-02-02       Impact factor: 5.858

3.  Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase.

Authors:  Feng Huang; Weihui Li; Hui Xu; Huafeng Qin; Zheng-Guo He
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

4.  Insights into phosphate cooperativity and influence of substrate modifications on binding and catalysis of hexameric purine nucleoside phosphorylases.

Authors:  Priscila O de Giuseppe; Nadia H Martins; Andreia N Meza; Camila R dos Santos; Humberto D'Muniz Pereira; Mario T Murakami
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

5.  Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.

Authors:  Maja Stipković Babić; Damjan Makuc; Janez Plavec; Tamara Martinović; Sandra Kraljević Pavelić; Krešimir Pavelić; Robert Snoeck; Graciela Andrei; Dominique Schols; Karlo Wittine; Mladen Mintas
Journal:  Eur J Med Chem       Date:  2015-08-10       Impact factor: 6.514

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.